Description: Segment 1 Fairley introduces the subject of the lecture and explains why one might expect to see antigens in malignant cells. He refers to an animal whose malignant cells were re-injected but which no longer grew into a tumour. Time start: 00:00:00:00 Time end: 00:05:27:21 Length: 00:05:27:21 Segment 2 Fairley shows a series of slides illustrating clinical signs of malignant melanoma. He refers in depth to an article by a plastic surgeon, Mr Bodenham, who showed evidence of cancer immunity occuring in the leg of a patient with malignant disease. Fairley then describes how antibodies against the tumour only occur in grade I and II disease. When the cancer has spread to become grade III, antibodies are no longer present. Time start: 00:05:27:21 Time end: 00:09:58:00 Length: 00:04:30:04 Segment 3 Fairley describes experiments in which lymphocyte cells have been shown to attack tumour cells. He then attempts to locate where in the body the immunological response occurs - evidence points to the fact that it is in the lymph nodes, leading Fairley to caution against removing cancer-free lymph nodes from women undergoing mastectomy. Time start: 00:09:58:00 Time end: 00:15:32:12 Length: 00:05:34:12 Segment 4 Fairley describes some problems with immunising against cancer cell proliferation one of which being the fact that immunity doesn't last very long so repeated treatments would be necessary. Time start: 00:15:32:12 Time end: 00:20:00:00 Length: 00:06:27:12 Segment 6 Fairley continues to discuss the research of George Mathe on children with acute leukaemia. He refers to graphs and charts which detail the results of Mathe's work comparing other factors in terms of survival rate such as immune therapy plus chemotherapy combined. Fairley concludes the lecture by stressing that at the present time, immunotherapy can only be used in conjunction with radio and chemotherapy. Time start: 00:24:35:00 Time end: 00:28:21:21 Length: 00:03:46:21